HomeMedical Pharmaceuticals

Category: Medical Pharmaceuticals

Curium Receives Positive CHMP Opinion...

f approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging notes Curium.

Menarini Group Shares New Analysis...

EMERALD Clinical Study is a Phase 3 registrational trial that demonstrated statistically significant PFS with elacestrant versus SOC endocrine monotherapy (fulvestrant, letrozole, anastrozole, exemestane). Based on these results, the U.S. Food & Drug Administration (FDA) approved ORSERDU (elacestrant) on January 27, 2023, for the treatment of postmenopausal women or adult men with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. 

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent

f approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging notes Curium.

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific Antigen (PSA) Levels After Primary Treatment With Curative Intent

f approved for Europe, PYLCLARI® (INN: Piflufolastat (18F) formerly known as [18F]-DCFPyL) will offer prostate cancer patients access to a diagnostic imaging agent more sensitive than conventional imaging notes Curium.

Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023

EMERALD Clinical Study is a Phase 3 registrational trial that demonstrated statistically significant PFS with elacestrant versus SOC endocrine monotherapy (fulvestrant, letrozole, anastrozole, exemestane). Based on these results, the U.S. Food & Drug Administration (FDA) approved ORSERDU (elacestrant) on January 27, 2023, for the treatment of postmenopausal women or adult men with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. 

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update

Shuttle Pharmaceuticals was founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT).

Novavax’s Nuvaxovid ™ Receives Positive CHMP Opinion for Full Marketing Authorization for the Prevention of COVID in the EU

Nuvaxovid NVX-CoV2373 is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID.

Nexus Pharmaceuticals Announces Launch of Potassium Chloride in Water for Injection

Potassium Chloride Injection is indicated in the treatment of potassium deficiency states when oral replacement is not feasible.

TempraMed’s VIVI Cap 1 Can Change the Way People Who Inject Insulin Live their Lives

The VIVI Cap 1 shields insulin in-use from potential temperature damage. Thus, reducing the risk of using damaged insulin and wasting money from discarded insulin that might have been compromised.

Relation Therapeutics Teams Up with Mila in Coalition to Identify COVID-19 Therapeutic Candidates

Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics, with the overall scientific direction by Mila founder Professor Yoshua Bengio.

MEDISCA Names Reflex Medical as Exclusive Partner for SAMIX Mixer Repair

As the sole distributor of SAMIX mixing machines to the compounding market in the United States and Canada, MEDISCA, a global leader in the personalized pharmaceutical industry, announced an exclusive partnership with Reflex Medical for all repair and servicing of SAMIX machines or otherwise known as electronic mortar and pestle mixers. Designed for use by compounding pharmacists, the SAMIX mixer utilizes evaporation and contamination-free mixing jars that serve as a convenient and hygienic method for dispensing personalized medications. MEDISCA spent...

By using this website you agree to accept Medical Device News Magazine Privacy Policy